Rice University bioengineers receive $1.4M to combat osteoarthritis

The FDA be­lieves that the ben­e­fit of CAR-T ther­a­pies con­tin­ues to out­weigh their risks amid an on­go­ing in­ves­ti­ga­tion on cas­es of sec­ond blood can­cers de­vel­op­ing

Re­gen­eron might be ready for com­pe­ti­tion with its block­buster drug Eylea, but it’s not clear that in­vestors are. On Thurs­day morn­ing, the biotech’s lead­er­ship field­ed

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) The 2023 cal­en­dar year ends as it